Upcoming FDA Feedback and the Future of Chemomab Therapeutics
As Chemomab continues to develop medical treatments against rare medical diseases, the future of this biotech company depends on the success of CM-101. CM-101 is a monoclonal antibody that has been developed by Chemomab which has shown remarkable progress in treating the symptoms of PSC. The company is eagerly waiting for upcoming feedback from the…